Valvular & structural heart disease

Incidence, Predictors, and Prognostic Impact of Bleeding Events After Transcatheter Aortic Valve Replacement (TAVR) According to VARC-3 Criteria

JACC Cardiovasc IntervPublished Prospective cohort study

Authors' conclusion

Bleeding events after TAVR were associated with poorer short- and long-term survival. The magnitude of this correlation was proportional to bleeding severity defined according to VARC-3 criteria.

Study context

Population
Patients with severe symptomatic AS undergoing TAVR
Participants
2,384 consecutive patients
Exposure
Bleeding events vs no bleeding after TAVR
  • Type 1n = 169
  • Type 2n = 399
  • Type 3n = 149
  • Type 4n = 44
Outcome
Incidence, predictors and clinical impact of bleeding events (VARC-3)
Follow-up
24 [IQR: 12-43] months
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

Bleeding events (VARC-3) by type
Any bleeding event
761 patients (31.9%)
Type 1 bleeding
169 (22.2%)
Type 2 bleeding
399 (52.4%)
Type 3 bleeding
149 (19.6%)
Type 4 bleeding
44 (5.8%)

Observational data: associations, not effects.

Further findings

Mortality by bleeding type · 30-day and 1-year

HR (95% CI)P value
Type 230-day2.94 (1.43–6.03)P = 0.003
Type 330-day4.91 (2.19–11.03)P < 0.001
Type 21-year1.86 (1.28–2.69)P = 0.001
Type 31-year2.28 (1.41–3.66)P = 0.001

Predictors of early bleeding

Female sex, thoracotomy access, larger (14-F) sheath, DAPT increased risk
P < 0.02 for all
Radial artery secondary access reduced risk
P < 0.001

Early bleeding incidence, VARC-2 vs VARC-3

Lower global incidence with VARC-2 (19% vs 27%)
P < 0.001
  • Similar prognostic pattern with VARC-2

Original publication

Incidence, Predictors, and Prognostic Impact of Bleeding Events After TAVR According to VARC-3 Criteria. JACC Cardiovasc Interv. Published 6 September 2023. doi:10.1016/j.jcin.2023.07.005

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.